Juliana Inoue

Dr. Juliana Inoue

Institute of Tropical Medicine, Universitätsklinikum Tübingen, Tübingen, Baden-Württemberg, Germany
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2024 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
JIJuliana Inoue
Juliana Inoue
AGAnnika Galys
Annika Galys
MRMiriam Rodi
Miriam Rodi
DMDorothea Ekoka Mbassi
Dorothea Ekoka Mbassi
Ghyslain Mombo-NgomaGhyslain Mombo-Ngoma
Ghyslain Mombo-Ngoma
JHJana Held
Jana Held
Objectives: We investigated the diversity and dynamics of Plasmodium infection in serially collected samples from asymptomatic participants of a clinical trial assessing the efficacy and safety of ivermectin in Gabon. We checked whether the baseline sample reflected the P. falciparum genotype and Plasmodium species diversity seen over 7 days of follow-up. Methods: Blood samples were collected at inclusion, every 8 hours until hour 72, daily until day 7, and on day 14. Plasmodium species was determined by qPCR and pfmsp1 length polymorphism was assessed for P. falciparum genotyping. Results: In 17/48 (35%) individuals, all pfmsp1 genotypes identified during the assessed period were detected at baseline; in 31/48 (65%), new genotypes were found during follow-up. Additional sampling at hour 24 allowed the identification of all genotypes seen over 7 days in 50% of the individuals. Ivermectin did not impact the genotype dynamics. Mixed Plasmodium spp. infections were detected in 28/49 (57%) individuals at baseline, and detection of non- falciparum infections during follow-up varied. Conclusions: Our results reveal complex intra-host dynamics of P. falciparum genotypes and Plasmodium species and underscore the importance of serial sampling in clinical trials for antimalarial drugs with asymptomatically P. falciparum -infected individuals. This might allow a more accurate identification of genotypes in multiple infections, impacting the assessment of drug efficacy. (c) 2024 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )

Verified
Journal Article
Open access
PDF file
JIJuliana Inoue
Juliana Inoue
MRMiriam Rodi
Miriam Rodi
TBTowanou Emmanuel Francis Bohissou
Towanou Emmanuel Francis Bohissou
LCLais Pessanha De Carvalho
Lais Pessanha De Carvalho
KLKatharina Lohse
Katharina Lohse
JHJana Held
Jana Held
The emergence of chloroquine-resistant Plasmodium falciparum in the 1950s posed a global threat to malaria control. Ceasing chloroquine use restored chloroquine-sensitive strains in many African countries. To assess whether chloroquine sensitivity re-emerged in Lambaréné, Gabon, we compiled published and new data on P. falciparum ex vivo chloroquine susceptibility, quantified as half-maximal inhibitory concentration (IC50), from four time points between 2004 and 2024. We then assessed the prevalence of pfcrt and pfmdr1 polymorphisms associated with chloroquine resistance via real-time PCR and Sanger sequencing, respectively, at six different time points between 2009 and 2024. Ex vivo chloroquine susceptibility data revealed a stepwise decrease in the median chloroquine IC50 from 2004 (113.8 nM; IQR: 79.6–163.5 nM, n = 42), 2009 (46.7 nM; IQR: 27.4–76.9 nM, n = 26), and 2017–2018 (15.6 nM; IQR: 6.1–40.9 nM, n = 46) to 2024 (2.1 nM; IQR: 0.8–6.1 nM, n = 39). The chloroquine-sensitive pfcrt haplotype CVMNK increased from 3.6% (1/28) in 2009 to 98.2% (56/57) in 2024, as well as the wild-type pfmdr1 N86 (23.1% (6/16), 2009; 100% (19/19), 2024). Paired molecular and ex vivo analyses revealed an association between IC50 values and CVMNK pfcrt and pfmdr1 N86. Our data provide evidence for the reestablishment of chloroquine-sensitive P. falciparum in Lambaréné, Gabon.

23 April 2026 in Tropical Medicine & International Health
Verified
Journal Article
Open access
PDF file
GMGabriel Montoia
Gabriel Montoia
MSMaria Carmen Arroyo Sanchez
Maria Carmen Arroyo Sanchez
GLGiselle Lima‐Cooper
Giselle Lima‐Cooper
MFMaria de Lourdes Rego Neves Farinas
Maria de Lourdes Rego Neves Farinas
JIJuliana Inoue
Juliana Inoue
SSSilvia Maria Di Santi
Silvia Maria Di Santi
Objectives: This study aimed to describe the cross‐reactivity of the Abbott Bioline Malaria Ag P.f/P.f/P.v rapid diagnostic test, designed to detect Plasmodium falciparum and P. vivax , with other Plasmodium species, based on the detection of parasite lactate dehydrogenase enzymes. Methods: Blood samples from 40 patients with positive thick and thin blood smear results were analysed: 10 infected with P. falciparum , 10 with P. vivax , 15 with P. malariae and five with P. ovale . Parasitemia was quantified as parasites/μL of blood. All samples were tested using the Abbott Bioline Malaria Ag P.f/P.f/P.v RDT, and species identification was confirmed by nested PCR. To compare test line intensities and assess potential nonspecific reactions, images of the RDT lines were analysed using ImageJ software. For statistical analyses, PCR was considered the gold standard. Sensitivity, specificity and accuracy were calculated using MedCalc 2026. Fisher's exact test was applied using GraphPad/Quick Calcs to compare the specificity of the anti‐Pf‐pLDH antibodies, with a significance level of 0.05 ( p < 0.05). Results: The RDT accurately detected all P. falciparum and P. vivax samples. However, 12 of 14 P. malariae samples yielded positive results on the T2 line, intended to be specific for Pf‐pLDH, as did four P. ovale isolates. The specificity of the anti‐Pf‐pLDH monoclonal antibodies against P. malariae was only 14.29% ( p < 0.05). ImageJ analysis showed that the T2 line signal intensity in P. malariae ‐infected samples exceeded that observed in P. falciparum –infected samples. Conclusions: This study provides the first evidence of cross‐reactivity of anti–Pf‐pLDH monoclonal antibodies in the Abbott Bioline Malaria Ag P.f/P.f/P.v RDT with P. malariae and P. ovale isolates. Moreover, highlights the imperative need to validate alternative biomarkers and novel point‐of‐care platforms, to enhance the rapid and accurate diagnosis of malaria, ensure species‐specific treatment and ultimately support effective malaria control and elimination strategies.

1 September 2026 in International Journal for Parasitology: Drugs and Drug Resistance
Verified
Journal Article
Open access
TBTowanou Emmanuel Francis Bohissou
Towanou Emmanuel Francis Bohissou
DNDiolinda Nahum
Diolinda Nahum
JIJuliana Inoue
Juliana Inoue
PSPaul Sondo
Paul Sondo
LHLazare Hounsou
Lazare Hounsou
JHJana Held
Jana Held

28 April 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MIMoses Ikegbunam
Moses Ikegbunam
VTVasileios Tzirtziganis
Vasileios Tzirtziganis
MRMiriam Rodi
Miriam Rodi
LALinda Anagua
Linda Anagua
LCLais Pessanha De Carvalho
Lais Pessanha De Carvalho
JHJana Held
Jana Held
Artemisinin-based combination therapies (ACTs) are currently the first-line treatment for uncomplicated malaria. However, ACTs are being threatened by the emergence of Plasmodium falciparum strains resistant to artemisinins as well as their partner drugs. Periodical surveillance of drug efficacy and molecular markers associated with resistance is required to monitor this. Resistance to piperaquine (PPQ), the partner drug in the ACT dihydroartemisinin-piperaquine, is spreading in Asia, and mutations associated with PPQ resistance have been reported in some African countries. In Nigeria, this has never been reported. This study aimed to assess markers of PPQ resistance—specifically, the T93S, H97Y, and F145I SNPs in exons 2 and 3 of the P. falciparum chloroquine resistance transporter (pfcrt) gene—and to examine amplification of the plasmepsin 2 and 3 genes (pfpm2/3) in 268 patient samples collected from Nnewi, Southeastern Nigeria, in 2019. SNPs were identified using PCR followed by sequencing, while pfpm2/3 copy number was determined by qPCR. No pfcrt SNPs of interest were detected, and no increase in copy number for pfpm2 or pfpm3 was observed in any sample. The absence of these PPQ resistance markers suggests that PPQ remains an effective partner drug in ACTs in this region. However, continuous monitoring of circulating P. falciparum parasites in Nigeria is crucial to promptly detect and respond to potential resistance development.

17 December 2023 in BMJ Global Health
Verified
Conference Paper
Open access
PDF file
FBFrancis Bohissou
Francis Bohissou
PSPaul Sondo
Paul Sondo
JIJuliana Inoue
Juliana Inoue
TRToussaint Rouamba
Toussaint Rouamba
SBSteffen Borrmann
Steffen Borrmann
JHJana Held
Jana Held
Background Despite various efforts to control malaria among children, the disease remains a leading cause of morbidity and mortality worldwide. In the Sahel region, including Burkina Faso, seasonal malaria chemoprevention (SMC) using Sulfadoxine-Pyrimethamine (SP) and Amodiaquine has been implemented since 2014. However, introducing this new strategy may lead to the spread of Plasmodium falciparum resistance to SP. This study analyses the mutations in SP resistance genes, dihydrofolate reductase (Pfdhfr) and dihydropteroate synthase (Pfdhps) before and after adopting SMC in Burkina Faso. Methods Dried blood spots obtained from previous studies conducted in Nanoro from 2010 to 2020 were randomly selected. Out of this selection, 769 Plasmodium falciparum isolates were retained, with 299 collected between 2010–2012 before the SMC adoption and 470 collected between 2018–2020 after the SMC implementation in 2014. The Pfdhps and Pfdhfr genes were amplified using nested PCR, and mutations that confer resistance were identified by sequencing the resulting products. Results The prevalence of Pfdhfr triple mutations (CIRNI) increased from 44.4% before the adoption of SMC to 84.4% following its implementation (p<0.0001). There were no mutations at codon Pfdhps 540; those at Pfdhps 581 remained rare and were reported exclusively after the SMC implementation (2.8%). The prevalence of haplotypes observed for the Pfdhps gene did not differ significantly over time. However, the Pfdhps haplotype quadruple mutant VAAKGS recently reported in Nigeria was found only in 2020 (1.4%). The combined Pfdhfr/Pfdhps quadruple mutant IRN/AAKA was the most common and increased following SMC implementation (44.9% vs 16.5%; p<0.0001). Conclusion After the SMC implementation, the prevalence of Pyrimethamine resistance markers increased significantly, while no difference was observed for Sulfadoxine resistance markers. Nevertheless, the detection in 2020 of the emerging Pfdhps haplotypes highlights the need to monitor SP resistance continuously. Funding: PAMAFRICA/EDCTP